Lai, B.; Mei, C.; Yan, X.; Chen, L.; Wang, Y.; Sheng, L.; Tang, S.; Mao, L.; Zhang, P.; Sun, Y.;
et al. 15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study. Cancers 2026, 18, 159.
https://doi.org/10.3390/cancers18010159
AMA Style
Lai B, Mei C, Yan X, Chen L, Wang Y, Sheng L, Tang S, Mao L, Zhang P, Sun Y,
et al. 15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study. Cancers. 2026; 18(1):159.
https://doi.org/10.3390/cancers18010159
Chicago/Turabian Style
Lai, Binbin, Chen Mei, Xiao Yan, Lieguang Chen, Yi Wang, Lixia Sheng, Shanhao Tang, Liping Mao, Ping Zhang, Yongcheng Sun,
and et al. 2026. "15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study" Cancers 18, no. 1: 159.
https://doi.org/10.3390/cancers18010159
APA Style
Lai, B., Mei, C., Yan, X., Chen, L., Wang, Y., Sheng, L., Tang, S., Mao, L., Zhang, P., Sun, Y., Xie, W., Zhou, D., Mai, W., Wang, H., Ma, L., Lou, Y., Wu, W., Jiang, H., Zhang, J.,
... Ouyang, G.
(2026). 15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study. Cancers, 18(1), 159.
https://doi.org/10.3390/cancers18010159
